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Single-chain variable fragments, diabodies and chim- 
eric antibodies (mouse variable domains and human 
immunoglobulin constant domains) were engineered 
by DNA recombinant technique and expressed transi- 
ently in tobacco leaves. The plants expressed the three 
types of antigen-binding moieties, accurately and 
faithfully. The yield obtained was 32 mg, 40 mg and 
20 mg respectively, per kg of wet weight of leaves. The 
chimeric antibody had high affinity for human chori-
onic gonadotropin (Ka = 1.9 ´ 1010 M–1). All three 
forms of the recombinant antibodies expressed by 
plants inhibited the binding of hCG to receptor on 
Leydig cells. 
SEROTHERAPY has been employed for life-threatening 
infections since the 1890s for tetanus, diphtheria and  
rabies. Initially antibodies raised in horses were emplo- 
yed, which limited the repeat use of such antibodies for 
therapeutic interventions owing to sensitization caused in  
recipients, to the heterospecies proteins. In recent years 
antibodies used as a last resort at the terminal stage of 
infections are derived from human sera prepared from 
hyper-immunized donors. These are consequently expen-
sive. However for snakebites, horse continues to be the 
source of serum for therapy. The contention of this article 
is to propose and demonstrate that humanized therapeutic 
antibodies can be made by recombinant DNA route. Fur-
thermore, plants can be used for expression of the recom- 
binant antibodies. Plants offer several advantages.  
Besides being eco-friendly, plant-derived immunoglobu-
lins would be expected to be devoid of harmful endo- 
toxins and animal viruses present in the commonly used 
prokaryotic or animal cell culture expression systems. 
We describe the successful production of recombinant 
antibodies against the human chorionic gonadotropin 
(hCG), employing plants as an expression system. Also 
illustrated are the different constructs of antigen-binding 
fragments that can be engineered and their relative merits 
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as functional antibodies. The data presented bring out the 
exquisite ability of plants to make antibodies. The plant 
machinery not only expresses the heavy and light chains 
of the immunoglobulin molecule, but also assembles 
them correctly to generate functional antibodies.  
 hCG is made by the human embryo before its nidation 
on the endometrium1. It has an essential role in the  
implantation of the embryo to initiate pregnancy. Anti- 
bodies against hCG prevent implantation in marmosets2 
and in humans3, as women immunized witha vaccine 
generating antibodies against hCG do not become preg-
nant, have regular menstrual cycles and show no length-
ening of the luteal phase4,5. Anti-hCG antibodies can thus 
be used for control of fertility. Ectopic production of 
hCG and/or its subunits ha  also been observed in several 
cancers. Malignant tumours of the bladder, pancreas, 
uterus and lung predominantly secrete the free beta sub-
unit, especially at the aggressive stage of metastasis6,7.  
 The use of antibodies, in particular monoclonal anti-
bodies, in diagnostics is widely prevalent. Of late their 
use for therapy of cancer8–11, autoimmune disorders12, 
allergies13 and prevention of transplant rejection14, is 
gaining ground. Thus there is the need for large-scale 
production of antibodies at low cost. Bacterial expression 
systems are routinely used for large-sc le xpression of 
antibody fragments like single-chain variable fragments 
(scFv), Fab and diabody fragments, but these organisms 
are unable to produce multimeric full-size antibody 
molecules. Yeast15 and insect cells16 have been used, 
though to a limited extent, to express complex antibody 
molecules. Mammalian cell culture system for expression 
of antibodies is established, but is expensive in addition 
to the risk of carrying over contaminating infectious 
agents. We demonstrate in this communication the expre- 
ssion at high yields of functional anti-hCG recombinant 
antibodies in plants. 
 The starting point of this work was a mouse mono-
clonal antibody reactive with hCG with a high affinity 
(Ka = 3 ´  1010 M–1) and specificity17. The genes coding 
for the antigen-binding regions, the variable domains, of 
the heavy and light chains of this antibody were isolated 
from the mRNA of the hybridoma cells which are primar-
ily engaged in making uniquely this antibody. cDNA was 
prepared by RT–PCR, using primers specific for constant 
domain of mouse IgG1 and kappa chains. T e immuno- 
globulin heavy and light chain variable domains were 
amplified by PCR and cloned for the construction of the 
following three types of antigen-b nding molecules: (i) 
the single chain variable fragment18 (scFv), where the 
variable heavy (VH) and light (VL) chain domains are 
linked together through an 18-amino acid flexible linker 
sequence and which can fold to form a single antigen 
binding site; (ii) the diabody19, where the VH and VL  
domains are separated by a shorter 8-amino acid linker 
sequence, forcing the domains to pair with complemen-
tary domains of another such fragment, to form two anti-
gen binding sites; (iii) the chimeric antibody, a full size 
antibody consisting of the murine VH and VL domains 
linked to the human IgG1 and kappa constant domains, 
respectively. 
 In order to determine that the constructs would be syn-
thes zed as recombinant antibodies (rAbs), scFv and  
diabody fragments were first cloned in a bacterial expres-
sion vector pSin1 (ref. 20), which has the His-6 tag and 
wer  expressed in E. coli (HB2151). For expression of 
the antibody fragments, the bacterial cultures were indu- 
ced with 1 mM IPTG and 0.4 M sucrose, for 3 h at 28–
30°C or overnight at the same temperature. The rAbs 
were obtained from the extract of bacterial periplasm 
(when induced for a period of 3 h) or were secreted into 
the culture medium on overnight i duction.  
 The periplasmic extracts were prepared from cells har-
vested after 3 h of induction. The cell pellet was resus-
pended in 5 ml of cold Tris buffer (30 mM Tris, 20% 
(w/v) sucrose, pH 8.0) and EDTA added to a final con-
centration of 1 mM. The suspension was incubated at 4°C 
for 15 min with gentle agitation followed by centrifuga-
tion (8000 g/4°C/20 min). The supernatant thus obtained 
was removed and kept on ice. The remaining pellet was 
resuspended in 5 ml of 5 mM MgSO4 and EDTA added 
to the suspension to a final concentration of 1 mM. This 
was followed by incubation at 4°C for 15 min and cen-
trifugation as before. This supernatant was mixed with 
the first supernatant. The mixture of cold osmotic shock 
fluid was dialysed against PBS and affinity purified. The 
purification was carried out using Ni-NTA agarose 
(Qiage ) according to manufacturer’s protocol.  
 The functionality of the rAbs was tested for hCG bind-
ing in direct-binding ELISA and in competition ELISA21 
against the parent mouse monoclonal antibody.  
 For the chimeric antibody, the heavy and light chain 
constructs were cloned directly in a plant expression vec-
tor, pSSH1 (ref. 22), since these would not be properly 
folded and assembled together in bacteria. In order to 
determine the comparative yields and functional quali-
ties, the scFv and diabody genes were also cloned indi-
vidually into the plant expression vectors. Figure 1 gives 
the constructs in the plant expression vector, pSSH1. 
These constructs were electroporated into Agrobacte-
rium. 
 The Agrobacterium carrying the expression constructs 
was vacuum-infiltrated23 into Nicotiana tobacum leaves. 
For the chimeric antibody, Agrobacteria carrying the 
chimeric heavy and light chain constructs were infiltrated 
either individually or together for expressing the full size 
chimeric antibody. Extracts from infiltrated leaves were 
prepared according to Vaquero et al.24 and tested for hCG 
binding in ELISA, for analysis by Western blot or for 
affinity purification. The his-6-tagged plant-expressed 
scFv and diabody were purified using Ni-NTA matrix, as 
befor . The full size chimeric antibody was purified  
using Protein-A matrix (Pharmacia) from leaves co-infil- 
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trated with the Agrobacterium carrying chimeric heavy 
and light chain constructs. The purity of the samples was 
analysed on SDS–PAGE and is depicted in Figure 2.  
 BCA reagent (Pierce) was used for quantification of 
protein concentration according to manufacturer’s ins ru- 
ctions, using bovine gamma globulin as a standard. 
 For capture ELISA, ELISA plate wells were coated 
with goat anti-human F(ab)2 [GAH-F(ab)2] or Fc [GAH-
Fc] specific antibody (1 mg/ml). The leaf extract, diluted 
in phosphate buffered saline containing 0.05% Tween-20, 
was applied to the wells. Detection of the bound light and 
heavy chains was carried out by using GAH-F(ab)2 alka-
line phosphatase (AP) conjugated antibody and GAH-Fc-
AP conjugated antibody, respectively. The substrate used 
for the AP label was 1 mg/ml p-nitrophenyl phosphate 
(Sigma) in substrate buffer. The absorbance was meas-
ured at 405 nm. 
 Bioneutralization capacity of the antibodies was d ter- 
mined by testing their ability to inhibit the binding of 
125I-labelled hCG to rat testicular receptors, following  
the procedure described by Pal et l.25. Bioneutralizat- 
ion capacity was plotted as percentage of inhibition of 
binding of hCG to receptor, against antibody concentra-
tion. 
 The plant leaves expressed all the antigen-bi ding 
molecules, namely the scFv, diabody and the chimeric 
antibody. Moreover, the yield of scFv was 32mg of puri-
fied fragment per kg of fresh weight of leaves in contrast 
to 150 ìg obtained from a litre of E. coli culture. The 
yield of diabody was even higher, i.e. 40mg per kg of 
fresh weight of leaves, whereas in E. coli the diabodies 
were expressed to the extent of 50 ìg per litre of bacte-
rial culture. 
 As regards the chimeric anti-hCG antibody, the chim- 
eric light (mouse VL domain and human kappa domain) 
and the chimeric heavy (mouse VH domain and the hu-
man IgG1 domain) chains were expressed in tobacco 
leaves when the Agrobacteria cultures carrying the respe- 
ctive constructs were vacuum-infiltrated individually, as 
is evident from Figure 3. However these chains did not 
bind hCG. When these were co-infiltrated, fully func-
tional chimeric antibodies efficiently binding hCG were 
generated, as seen from the data in Figure 4. The plant 
leaves therefore have the capability to assemble the full 
heavy and light chains of an antibody, in a functional way. 
 
 
 
 
Figure 1. pSSHI plant expression vector constructs for the anti-hCG 
recombinant antibodies. The single chain variable fragment (scFv) and 
diabody genes were cloned downstream of the cauliflower mosaic virus 
35S enhanced promoter (35SS promoter), the 5¢ untranslated region 
(UTR) of chalcone synthase (CHS), the plant codon optimized leader 
peptide (LPH) of heavy chain of murine antibody mAb24 (ref. 22), and 
upstream of the his-6 tag for detection and purification. KDEL is the 
signal for endoplasmic reticulum retention and the 3¢ UTR is from the 
tobacco mosaic virus. The chimeric heavy and light chains were simi-
larly cloned in the pSSH1 vector, except that the leader peptide (LPL) 
was from the light chain of the murine mAb24. 
 
 
 
 
Figure 2. Affinity-purified plant-expressed recombinant anti-hCG antibodies. The recombinant anti-
bodies were purified from tobacco leaves, vacuum-infiltrated with Agrobacterium carrying the vector 
constructs for single chain variable fragment (scFv), diabody and co-infiltration f chimeric heavy chain 
(HC) and chimeric light chain (LC). The his-6-tagged scFv (a) and diabody (b) proteins were purified  
using a Ni-NTA matrix, which gave essentially pure antibody fragments. The minor second bands are due 
to differential degree of glycosylation of these fragments. The chimeric antibody (c) was affinity purified 
using Protein-A matrix. Note the major band of the heavy and light chains of the immunoglobulin obta- 
ined by SDS–PAGE.  
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 The plant-expressed scFv, diabody and chimeric anti-
bodies all bound to hCG in immunoassays. It was how-
ever important to determine whether such antigen-
binding moieties can effectively inhibit the bioactivity f 
hCG. This was determined by studying the ability of the 
antibodies to prevent the binding of hCG to its receptors 
on target tissues. hCG binds to its receptors with fairly 
high affinity (Ka = 109 M–1), and unless the antibody has 
equivalent or higher affinity, the binding of hCG to its 
receptor will not be inhibited. Data in Figure 5 show that 
all three antigen-bi ding molecules produced in plants 
successfully inhibited the binding of hCG to Leydig cell 
receptors. The inhibitory capacity however diff red. The 
full size chimeric antibody is most effectiv  with an ID50 
of 10–10 M. The scFv and diabody, though effective, rqu- 
ired more than 100 times higher concentration. The bind-
ing of hormone to its receptor is the first critical step for 
its action on the cell. The fact that the inhibition of this 
step leads also to blockage of the subsequent effects, 
namely hCG-induced testosterone synthesis, has been 
reported elsewhere21.  
 Data reported in this communication clearly demon-
strate the ability of plant leaves to express antigen-
binding fragments like scFv and diabodies. In contrast to 
bacterial systems, plants expressed these rAbs with much 
higher yield. Plants also express the full avy and light 
chains, which are not made in prokaryotic expression 
systems. The light chain expressed individually is unable 
to bind the antigen, in spite of the presence of compl- 
 
 
 
 
Figure 3. Individual expression, as proteins, of light and heavy 
chains in plant leaves. The extract obtained from leaves infiltrated with 
Agrobacterium carrying the individual chimeric heavy and light chains 
or co-infiltration of the two cultures, was used in capture ELISA (des- 
cribed in the text). The light chain (LC) was captured efficiently only 
by the antibody specific to human F(ab)2 fragment. On the other hand, 
the heavy chain (HC) bound antibodies are specific to the human Fc 
region and the F(ab)2 fragment. The heavy and light chains (HC + LC) 
in extracts obtained from leaves co-infiltrated with the two constructs, 
bound successfully to both the antibodies. The non-infiltrated (NI) leaf 
extract was used as control. 
mentarity determining regions (CDRs) in the molecule. 
The same is the case with the heavy chain, though this 
chai  at high concentrations has the property of binding 
the antigen to a small extent. The full function of binding 
efficiently emerges by the combination of heavy and 
light chains. This becomes possible when Agrobacteria 
containing both constructs are co-infiltrated into plant 
leaves. The combination of heavy and light chains  
demands the creation of three disulphide bonds, which is 
accurately achieved in these otherwise mammalian pro-
teins, by plant cells. The yield of pure chimeric antibody 
was 20–24 mg per kg of fresh weight of leaves. Thus 
plants can be a cost-effective source of such recombinant 
antibodies. Preliminary investigations also show that 
these antibodies can be expressed in non-tobacco plant 
leaves, like spinach and brinjal. However, further studies 
are required to identify non-tobacco plants giving equally 
high, f not better yields. 
The three types of recombinant antigen-binding frag-
ments expressed in plants retain their ability to bind hCG. 
The avidity of binding however differed, with the chi-
meric antibody having the highest affinity amongst the 
three. The diabody was nearly as efficient as the scFv, 
though somewhat better. The three variant forms of the 
antibody molecule have different applications. The full 
antibody does not normally penetrate all cells, except 
tho e having Fc receptors. Studies have shown that 
sm ller antigen-bi ding fragments (60–10  kDa) have 
greater tumour penetration ability than the full size anti-
bodies (150 kDa)26–28. Pharmacokinetic studies have 
demonstrated that these have different clearance rates. 
 
 
 
 
Figure 4. hCG binding ability of transiently expressed chimeric 
heavy and light chains. The chimeric heavy (HC) and light (LC) chain 
constructs were infiltrated individually or together into tobacco leaves. 
Extracts prepared from HC, LC, HC + LC and non-infiltrated tobacco 
leaves were tested for hCG binding in ELISA. The heavy chain alone, 
at high concentrations, binds hCG to some extent; but the leaf extract 
prepared from leaves co-infiltrated with HC- and LC-containing Agro-
bacterium, showed significant binding to hCG. Thus both the heavy 
and light chains are required for efficient hCG-binding activity. 
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Figure 5. Inhibition of binding of hCG to receptors on Leydig cells. 
Testicular receptors prepared from Wistar rats were incubated with 
125I-labelled hCG in absence or presenc  of varying concentrations of 
the plant-expressed rAbs. The percentage of inhibition was calculated 
with respect to maximal binding of labelled hCG to the receptor prepa-
ration. rAbs inhibited the binding of hCG to receptors in a dose-depen- 
dent manner. sPIPP and dPIPP showed 50% inhibition at 5.7 ´ 10–8 M 
and 2.1 ´ 10–8 M concentration respectively, whereas cPIPP was able to 
inhibit at a lower concentration of 1.1 ´ 10–10 M. 
 
 
 
The smaller fragments, scFvs and diabodies, have shorter 
half life and therefore are advantageous for in vivo diag-
nostic use as well for targeting radioisotopes to tumours, 
for therapy. 
 Plant-produced antibodies are well tolerated by humans 
and have been found effective in humans for preventing 
oral colonization of Streptococcus mutans29. Another 
plantibody has been reportedly effective in preventing 
vaginal herpes simplex virus (HSV-2) infection in mice30. 
Recombinant antibodies can be successfully folded and 
expressed in plants and have characteristics similar to 
those made by hybridomas or mammalian cell cul-
tures30,31. Expression in plants provides a suitable way for 
large-scale expression of antibodies at low cost and are 
free from contaminants such as endotoxins and animal 
viruses, possible in case of production in bacterial or ani-
mal cells.  
 Plant-produced anti-hCG antibodies have several pot- 
ential applications. On account of their low cost these can 
be used in immunodiagnostic kits for pregnancy and for 
detection and monitoring of hCG synthesizing cancers. A 
large number of cancers have been described which make 
hCG ectopically6,7,32–34. Thus the detection of hCG in 
non-pregnant states would be indicative of such malig-
nancies. Follow-up measurements can be useful for asse- 
ssing complete surgery and/or therapy by apropriate 
products. The rappearance of hCG would be indicative 
of metastasis. The use of antibodies against alpha or beta 
subunits for therapy of tumours needs further systematic 
studies. Antibodies against alpha subunit inhibited effec-
tively the growth of human Chago lung cancer cells, in 
culture and prevented, by passive administration of anti-
bodies, the uptake of the tumour in nude mice35. The re-
combinant anti-hCG antibodies therefore have potential 
use in diagnosis and therapy of hCG producing tumours, 
besides their obvious use for emergency contraception 
and for preventing pregnancy. While chimeric anti-hCG 
antibodies would be permitted for cancers, further huma- 
nization of the chimeric antibodies would be necessary 
for their use in control of fertility. 
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